恒瑞医药:季报点评:创新药研发管线稳步推进
恒瑞医药(600276) 中原证券·2024-11-22 17:13
分析师:李琳琳 登记编码:S0730511010010 lill@ccnew.com 021-50586983 化学制药 创新药研发管线 稳步推进 | --- | --- | --- | |-------------------------|------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...